Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Press release 2020-12-30

Xspray Pharma reports positive results from a study with dasatinib during omeprazole treatment

Regulatory press release 2020-12-29

Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia

Press release 2020-12-17

Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment

Regulatory press release 2020-12-11

Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application

Regulatory press release 2020-11-20

Xspray Pharma publishes Interim Report Q3, January – September 2020

Regulatory press release 2020-10-30

Number of shares and votes in Xspray

Press release 2020-10-21

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2021

Regulatory press release 2020-10-20

Xspray Pharma Has Carried Out a Directed Share Issue Raising Gross Proceeds of Approximately SEK 265 million

Regulatory press release 2020-10-20

Xspray Pharma Contemplates a Directed Share Issue

Regulatory press release 2020-09-30

Number of shares and votes in Xspray

Show more

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe

  • This field is for validation purposes and should be left unchanged.
  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com